Medidata Solutions (MDSO) Getting Somewhat Positive News Coverage, Report Shows

News coverage about Medidata Solutions (NASDAQ:MDSO) has been trending somewhat positive this week, Accern reports. The research firm rates the sentiment of press coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Medidata Solutions earned a media sentiment score of 0.08 on Accern’s scale. Accern also assigned news articles about the company an impact score of 45.918862146386 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.

Shares of Medidata Solutions opened at $76.43 on Friday, according to Medidata Solutions has a twelve month low of $75.30 and a twelve month high of $76.15. The company has a quick ratio of 1.63, a current ratio of 1.63 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $4.48 billion, a PE ratio of 89.92, a PEG ratio of 3.79 and a beta of 1.49.

Medidata Solutions (NASDAQ:MDSO) last issued its quarterly earnings results on Thursday, April 19th. The company reported $0.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.35 by $0.05. Medidata Solutions had a return on equity of 11.36% and a net margin of 7.96%. The business had revenue of $149.20 million during the quarter, compared to the consensus estimate of $146.73 million. During the same period in the previous year, the business earned $0.31 EPS. The business’s quarterly revenue was up 16.9% on a year-over-year basis. equities analysts forecast that Medidata Solutions will post 0.98 EPS for the current year.

Several research firms have issued reports on MDSO. Morgan Stanley dropped their price objective on Medidata Solutions from $86.00 to $79.00 and set an “overweight” rating on the stock in a report on Friday, February 9th. Dougherty & Co restated a “buy” rating and set a $89.00 price objective (up from $79.00) on shares of Medidata Solutions in a report on Thursday, May 10th. ValuEngine downgraded Medidata Solutions from a “hold” rating to a “sell” rating in a report on Thursday, March 1st. TheStreet upgraded Medidata Solutions from a “c+” rating to a “b-” rating in a report on Monday, March 12th. Finally, Zacks Investment Research downgraded Medidata Solutions from a “hold” rating to a “sell” rating in a report on Thursday, April 12th. Four analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. Medidata Solutions currently has an average rating of “Buy” and an average price target of $83.71.

In related news, CEO Tarek Sherif sold 26,836 shares of the company’s stock in a transaction on Monday, March 12th. The stock was sold at an average price of $70.25, for a total transaction of $1,885,229.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Michael I. Otner sold 10,395 shares of the company’s stock in a transaction on Wednesday, April 25th. The stock was sold at an average price of $70.05, for a total value of $728,169.75. Following the transaction, the executive vice president now owns 74,165 shares of the company’s stock, valued at $5,195,258.25. The disclosure for this sale can be found here. Insiders sold a total of 45,231 shares of company stock valued at $3,166,939 over the last quarter. Company insiders own 4.70% of the company’s stock.

Medidata Solutions Company Profile

Medidata Solutions, Inc provides cloud-based solutions for life sciences worldwide. It offers the Medidata Clinical Cloud, a platform, pioneering analytics, and clinical technology for the development of new therapies. The company's platform solutions include data capture and management and trial planning and management.

Insider Buying and Selling by Quarter for Medidata Solutions (NASDAQ:MDSO)

Receive News & Ratings for Medidata Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medidata Solutions and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit